We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

R-BIOPHARM

R-Biopharm AG is a biotechnology company that offers innovative products for numerous applications in the area of cli... read more Featured Products: More products

Download Mobile App




Rapid Commercial Test for Campylobacter Evaluated

By LabMedica International staff writers
Posted on 13 Feb 2014
The effectiveness of a new rapid immunochromatographic test for the qualitative detection of Campylobacter antigens in pathologic feces has been evaluated.

The genus Campylobacter belongs to the family Campylobacteriaceae and contains 18 species, including Campylobacter jejuni, the cause of around 90% of acute Campylobacter enteritis cases in humans, a zoonotic disease prevalent worldwide and transmitted via water and food.

Microbiologists at the Hospital Universitario Virgen de las Nieves (Granada, Spain) examined 300 consecutive samples of fresh feces samples from patients diagnosed with diarrhea in primary (57.6%) and specialist (42.4%) care; 50.6% were from adults and 49.4% from children under 14 years of age, between March and May 2013. They were processed for coproculture immediately on their reception by culture and colonies suspected of being enteropathogenic were identified by means of the Biotyper system (Bruker Daltonics; Billerica, MA, USA).

The RIDAQUICK Campylobacter immunochromatographic test (R-biopharm AG; Darmstadt, Germany) was evaluated and compared with culture results. Campylobacter was considered present when the microorganism was isolated or when the specific DNA was detected in samples with contradictory culture and immunochromatographic findings. The results of the RIDAQUICK Campylobacter test was considered positive when violet red lines could be seen in the control (C) and test (T) bands, negative when the control line alone appeared, and invalid when no line could be observed.

Campylobacter was detected in 37 (12.3%) of all samples, and the gold-standard culture method was positive for C. jejuni in 31 (83.78%) of these. A different enteropathogen was detected in 12 (8.11%) of the samples from children. The culture and immunochromatographic results differed in 12 samples (4% of the total), which were therefore studied by polymerase chain reaction (PCR); six of these samples were culture-negative and PCR-positive and one was culture positive (C. jejuni) and PCR-negative.

The diagnostic accuracy values of the RIDAQUICK Campylobacter assay versus culture were: sensitivity of 87%, specificity of 97%, and positive and negative predictive values of 77% and 98%, respectively. RIDAQUICK Campylobacter was found to be a rapid test for the diagnosis of enteritis due to Campylobacter and could be an option for the clinical diagnosis of one of the main causes of bacterial enteritis in resource-limited settings. The study was published in the February 2014 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Hospital Universitario Virgen de las Nieves
Bruker Daltonics
R-biopharm AG



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.